Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
American Heart Journal|May 5, 2024
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYNStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
American Heart Journal|December 24, 2024
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinicsAdam J Nelson, Lisa A Kaltenbach, Darren K McGuire, et al.
The Lancet Regional Health. Western Pacific|June 19, 2026
Systematic review of cardiovascular care delivery across health systems in the Asia-Pacific: a regional roadmap for strengthening cardiovascular careNicholas Ws Chew, Gwyneth Kong, F Aaysha Cader, et al.
Circulation|July 6, 2021
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology CommunityAdam J Nelson, Neha J Pagidipati, Vanita R Aroda, et al.
The New England Journal of Medicine|May 8, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
American Journal of Preventive Cardiology|August 14, 2025
Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trialAdam J Nelson, Lisa A Kaltenbach, Hussein R Al-Khalidi, et al.
Circulation. Genomic and Precision Medicine|November 29, 2024
Polygenic Prediction of Recurrent Events After Early-Onset Myocardial InfarctionMaddalena Ardissino, Elvezia Maria Paraboschi, Samuel A Lambert, et al.
Circulation|June 27, 2024
Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes TrialManasi Tannu, Lisa Kaltenbach, Neha J Pagidipati, et al.
Nature Medicine|February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialStephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
JAMA Network Open|February 17, 2022
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular DiseaseAdam J Nelson, Emily C O'Brien, Lisa A Kaltenbach, et al.
Pageof 18